The regulatory green light covers treatment for acute uncomplicated influenza and post-exposure prevention in patients aged 5 and older. By introducing a generic competitor, federal health officials aim to curb rising pharmaceutical costs and broaden patient access to the medication. This approval follows the agency's stated strategy of fostering market competition to ensure that essential antiviral treatments remain within reach for a wider demographic as seasonal outbreaks persist.
In section Market Quotes
FDA Clears First Generic Version of Single-Dose Flu Drug Xofluza
Patients facing the 2026-2027 flu season will soon have a more affordable alternative to Genentech’s Xofluza, as the FDA has granted approval for the first generic version of the single-dose treatment. Norwich Pharmaceuticals will manufacture the baloxavir marboxil tablets, marking a shift in the market for acute influenza therapy.
Comments (0)
No comments yet. Be the first!